bilaterals.org logo
bilaterals.org logo

India FTAs & medicines

Join the rally to oppose EU-India FTA!
9-Apr-2013
Around 2000 people including people living with HIV (PLHIV), patient groups and public health activists will take to the streets and rally from Barakhamba road to Jantar Mantar at 11.00 am on 10 April 2013 to voice concerns and protest against harmful provisions being pushed by the EU-India FTA negotiations
Manmohan Singh must learn from the Novartis judgement
2-Apr-2013 First Post
Will Manmohan Singh understand the clear purpose behind the national sentiment around the Supreme Court judgment on Novartis’ cancer drug Glivec? If he does, he should take a relook at the India-EU Free Trade Agreement that is cooking in his back-room.
European Union sets tough conditions under FTA
1-Apr-2013 LiveMint
The gains accruing to the Indian generic drugs industry as a result of the Supreme Court judgement on the Novartis case may be lost if India accepts demands by the European Union (EU) under the proposed free trade agreement (FTA) between the two sides.
Indian pharma sector fears India-European Union FTA could imperil local industry
27-Mar-2013
Drugmakers and healthcare activists are worried that the India-European Union Free Trade Agreement (FTA), which is in the works, may contain a provision that could imperil local industry and have urged the government to keep patent infringement issues out of FTAs.
European Union-India FTA may hit generic medical industry
21-Mar-2013
The free trade agreement that European Union is pushing India to sign could put an end to India’s status as the pharmacy of the developing providing affordable medicines, especially HIV drugs to countries like Brazil, Thailand, South Africa, Zimbabwe and several others. The negotiations with EU are on at a feverish pace this week in Brussels even before the parliamentary standing committee looking into the free trade agreements (FTAs) has submitted its report.
Pharma exports: India asks Japan to remove non-tariff barriers
2-Sep-2012
India has asked Japan to remove all non-tax barriers to help the domestic industry take advantage of the comprehensive free-trade agreement and increase share in the Japanese market.
Does EU/India free trade agreement spell the end of cheap drugs for poor countries?
10-Feb-2012
After four years of negotiations, campaigners fear India is about to sign a trade deal with the EU which will stop the flow of cheap life-saving drugs to the developing world
Act Up-Paris confront Karel De Gucht on ACTA and EU-India FTA
7-Feb-2012 ACT-UP Paris
Supporting the ongoing Global Week of Action on the EU-India FTA, Pauline Londeix of Act Up-Paris today confronted the European Commission for Trade, Karel de Gucht at a “Civil Society dialogue on Trade, Growth and development” at the European Commission. De Gucht reportedly leaves for India tomorrow for the EU-India Summit on 10th February 2012 where the E.C. is putting pressure on the Indian government to announce political trade-offs in the EU-India FTA.
NGO asks European Commission not to push India to accept IP provisions in EU-India FTA
15-Dec-2011 PharmaBiz
As the 14th round of negotiations on the EU-India free trade agreement is held in Delhi, an NGO working in the health sector has urged the European Union not to push India to accept IP provisions in the deal
EU-India FTA negotiations: DNP+ protest
9-Dec-2011
DNP+ believes that IP should be completely be removed from the trade negotiations.
Indian pharma industry to gain from free trade agreement with Gulf nations
13-Oct-2011 PTI
The Indian pharmaceuticals and chemicals industry will be among the biggest beneficiaries of a free trade agreement between the GCC and India, a leading banker in the region has said.
DoP to convey concerns of industry over proposed FTAs, TPPA to commerce ministry
10-Aug-2011 PharmaBiz
India’s Department of Pharmaceuticals will take up issues with the Commerce Ministry regarding the proposed Trans Pacific Partnership Agreement which is likely to have adverse impact on the Indian pharma products, and other such Free Trade Agreements in the pipeline.
EU-India FTA - the data exclusivity dilemma
15-Jul-2011 Public Service Europe
Conflict between European and Indian pharma industries might be played out again in FTAs with other nations
"BRICS can ensure affordable drugs"
10-Jul-2011
While ‘data exclusivity’ clauses will not feature in the India-European Union free trade agreement (FTA), the threat posed by the impending deal to the world’s supply of cheap generic drugs is far from over.
Millions will die if India stops AIDS drugs — UN
6-Jul-2011 Reuters
Millions of people dependent on life-saving generic drugs to treat HIV/AIDS will die if India stops producing cheap drugs for the disease due to its trade deal with the European Union, the head of UNAIDS warned on Tuesday.
India says ‘no’ to policy that would block access to affordable medicines
23-Jun-2011 MSF
India formally announced at the UN High Level Meeting on HIV and AIDS that it will not accept data exclusivity, a provision harmful to access to affordable medicines, as part of a free trade agreement currently being negotiated with the European Union.
Karl De Gucht writes Andris Piebalgs on topic of European Union IPR demands on India and other developing countries
29-May-2011 KEI
KEI has received a copy of a May 16, 2011 letter from Karl De Gucht to Andris Piebalgs, which discusses (1) the EU-India FTA, and (2) Relations between IPR and development policies.
India, Mercosur "must withstand EU pharma demands"
6-May-2011
Nations currently negotiating trade deals with the European Union (EU) have been warned that they must resist European demands which could threaten access to medicines in emerging and developing countries.
No compromise in our stance on IPR, says India
5-May-2011
India will not compromise its stand or take a position on intellectual property rights (IPR), especially on pharmaceuticals, beyond its domestic law and agreements as mandated under the aegis of the global trade body—World Trade Organization (WTO).
India-EU FTA carries severe public health consequences
12-Apr-2011 FSRN
After four years of talks, India and the European Union are narrowing down their differences on a bilateral Free Trade Agreement that critics in India and elsewhere say could have a devastating impact on public health by hampering access to life-saving drugs for millions of people.